V3V Stock Overview
VITA 34 AG engages in the collection, processing, and cryopreservation of stem cells from umbilical cord blood and tissue in Germany, Poland, Portugal, and internationally.
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 3/6 |
| Dividends | 0/6 |
VITA 34 AG Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | €4.50 |
| 52 Week High | €7.24 |
| 52 Week Low | €3.85 |
| Beta | 0.60 |
| 1 Month Change | -0.44% |
| 3 Month Change | -8.16% |
| 1 Year Change | -36.26% |
| 3 Year Change | -72.89% |
| 5 Year Change | -67.97% |
| Change since IPO | -64.90% |
Recent News & Updates
Recent updates
Shareholder Returns
| V3V | DE Healthcare | DE Market | |
|---|---|---|---|
| 7D | -7.4% | -1.3% | 2.5% |
| 1Y | -36.3% | -4.1% | 5.4% |
Return vs Industry: V3V underperformed the German Healthcare industry which returned -4.5% over the past year.
Return vs Market: V3V underperformed the German Market which returned 4.6% over the past year.
Price Volatility
| V3V volatility | |
|---|---|
| V3V Average Weekly Movement | 7.8% |
| Healthcare Industry Average Movement | 6.2% |
| Market Average Movement | 5.0% |
| 10% most volatile stocks in DE Market | 10.5% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: V3V has not had significant price volatility in the past 3 months.
Volatility Over Time: V3V's weekly volatility (8%) has been stable over the past year, but is still higher than 75% of German stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1997 | 745 | Jakub Baran | www.vita34.de |
VITA 34 AG engages in the collection, processing, and cryopreservation of stem cells from umbilical cord blood and tissue in Germany, Poland, Portugal, and internationally. It also develops products and drugs based on cells, tissues, and blood for medical applications; and produces viral vectors and CAR-T cells. The company manufactures advanced therapy medicinal products for third parties.
VITA 34 AG Fundamentals Summary
| V3V fundamental statistics | |
|---|---|
| Market cap | €81.23m |
| Earnings (TTM) | -€1.86m |
| Revenue (TTM) | €77.06m |
1.1x
P/S Ratio-43.6x
P/E RatioIs V3V overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| V3V income statement (TTM) | |
|---|---|
| Revenue | €77.06m |
| Cost of Revenue | €48.82m |
| Gross Profit | €28.24m |
| Other Expenses | €30.11m |
| Earnings | -€1.86m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
May 31, 2024
| Earnings per share (EPS) | -0.11 |
| Gross Margin | 36.65% |
| Net Profit Margin | -2.42% |
| Debt/Equity Ratio | 37.2% |
How did V3V perform over the long term?
See historical performance and comparison